Safe and tolerable one-hour pamidronate infusion for multiple myeloma patients
Dimitrios Chantzichristos, Andréasson Björn, Johansson Peter
Department of Internal Medicine, Uddevalla Hospital, Uddevalla, Sweden
Background: Once a month, patients with multiple myeloma received an infusion of bisphosphonates, principally to reduce osteoclastic bone resorption. Recommended infusion time for pamidronate is 2 hours in the US and 4 hours in Europe because of its potential nephrotoxicity. From 2003, a 90 mg infusion of pamidronate was provided over 1 hour to patients with no pre-existing renal impairment, in the Daily Care Unit at Uddevalla Hospital.
Method: Retrospective analysis of the renal deterioration, serum calcium, and adverse effects in patients with multiple myeloma treated with 1-hour pamidronate 90 mg infusion from January 2003 to April 2007.
Results: Seventy-nine patients provided valuable data. A total number of 846 infusions were given and the median number of infusion to each patient was 11. Significant creatinine elevation was seen in 7 patients (8.9%), after 19 infusions (2.2%). Renal deterioration occurred in 5 of these 7 patients, which was related to progress of the myeloma or opportunistic infections. Prevalence of infusion-related events was 0.8% and the mean total S-Ca was 0.05 mmol/L lower than the baseline.
Conclusion: Few events of renal deterioration, hypocalcemia, or other adverse effects resulted from a 1-hour pamidronate 90 mg infusion for multiple myeloma patients with no pre-existing renal impairment.
Keywords: bisphosphonates, pamidronate, multiple myeloma, infusion time
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF]
Readers of this article also read:
Kulkarni M, Flašker A, Lokar M, Mrak-Poljšak K, Mazare A, Artenjak A, Čučnik S, Kralj S, Velikonja A, Schmuki P, Kralj-Iglič V, Sodin-Semrl S, Iglič A
Published Date: 18 February 2015
Diagnostic accuracy of sensitive or high-sensitive troponin on presentation for myocardial infarction: a meta-analysis and systematic review
Sethi A, Bajaj A, Malhotra G, Arora RR, Khosla S
Published Date: 21 July 2014
Xia S, Li P, Chen Q, Armah M, Ying X, Wu J, Lai J
Published Date: 23 May 2014
Wang H, Gu W, Xiao N, Ye L, Xu Q
Published Date: 18 March 2014
NanoDisk containing super aggregated amphotericin B: a high therapeutic index antifungal formulation with enhanced potency
Burgess BL, He Y, Baker MM, Luo B, Carroll SF, Forte TM, Oda MN
Published Date: 12 December 2013
Bian X, Liang S, John J, Hsiao CH, Wei X, Liang D, Xie H
Published Date: 21 November 2013
Itakura M, Itakura H, Kashima T, Akiyama H, Kishi S
Published Date: 1 July 2013
Mª Rosa Güell Rous
Published Date: 6 June 2008
Prashant Kedia, Russell D Cohen
Published Date: 15 November 2007
Published Date: 15 July 2007